Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up

Major progress has occurred in multiple myeloma (MM) treatment in recent years, but this is not seen in low- and middle-income countries. MATERIALS AND METHODS: We retrospectively assessed the efficacy and safety of cyclophosphamide, thalidomide, and dexamethasone (cyclophosphamide 400 mg/m(2) for 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasquez, Jule, Ruiz, Rossana, Aliaga, Karina, Valencia, Fernando, Villena, Marco, Quintana, Shirley, Vidaurre, Tatiana, Casanova, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457778/
https://www.ncbi.nlm.nih.gov/pubmed/34297605
http://dx.doi.org/10.1200/GO.20.00665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457778/
https://www.ncbi.nlm.nih.gov/pubmed/34297605
http://dx.doi.org/10.1200/GO.20.00665

Ejemplares similares